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Abstract
Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-
seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated
with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management
of depression in a population reluctant to add another "pill" or another set of related side effects
to an already complex highly active antiretroviral therapy (HAART) regimen.
Methods:  The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression
Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after
initiation of treatment with SAM-e.
Results: Data show a significant acute reduction in depressive symptomatology, as measured by
both the HAM-D and the BDI instruments.
Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive
decreases in depression symptom rating scores throughout the 8 week study.
Background
The incidence of depression in people living with HIV
(PLWH) has consistently been reported to be higher than
the 12–15% rates reported for the general population [1].
Depression in this population is largely untreated. Esti-
mates suggest that this comorbid condition of HIV affects
10% – 50% of PLWH [2]. The management of depression
in people with HIV is important since it can reduce medi-
cation adherence. Depression can be life-threatening,
given that the patient can deteriorate medically, and that
untreated depression can result in suicide. Untreated
depression may also result in substance abuse, a theory
based on the 'self medication' theories of addictive behav-
ior. Depression is a pressing problem at this point in the
epidemic because the HIV population is aging and the
incidence of depression increases with age [3].
In New York City, 27% of all people living with HIV are
over 50 years of age and 66% are over 40 years age [4]. In
two studies of PLWH age 50 and older, the rate of depres-
sive symptomatology ranged from 58% – 68% [5].
Under-treated depression in the HIV population may be
the result of multiple factors. People of color, women,
substance abusers, and those living in poverty are less
likely to have access to or to accept mental health
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outpatient services [5-7]. Many patients with HIV who are
managing their disease are on complex regimens of med-
ications (HAART) and dietary supplements to treat their
illness [8]. Adding another pill with significant side effects
is often viewed by both patient and primary treating phy-
sician as an unacceptable burden, either in terms of
number of pills per day, or in terms of anticipated side-
effect profiles, or risk/benefit analysis [9]. Primary care
physicians are often unprepared to recognize depression,
which can present as fatigue, weakness, insomnia or loss
of appetite, and may seek medical explanations for
depressive symptoms [7]. HIV-related dementia, which
presents with apathy and amotivation, can also be mis-
taken for depression. Physicians may be unfamiliar with
mental health interventions and place depression as a
lower priority after management of the primary HIV infec-
tion [10]. The stigma of HIV remains large and the addi-
tion of the potential stigma of a mental illness (i.e.
depression) further contributes to the patient's reluctance
to pursue or engage treatments for depression [11]. Many
patients fear that substance abuse, homosexuality, or HIV
itself may be grounds for discrimination from a mental
health provider [12,13].
SAM-e is a compound that has been used for many years
in Europe as an antidepressant. It became available in the
USA as a non FDA-regulated compound in 1999. SAM-e
resembles a naturally occurring compound in the human
body, formed by methionine and adenosine triphos-
phate. SAM-e donates an active methyl group to several
acceptor molecules, including catecholamines, fatty acids,
phospholipids, proteins and nucleic acids [14]. SAM-e
appears to increase central turnover of dopamine and
serotonin; for example it increases the main metabolite of
central serotonin-5-HIAA (5-hydroxyindoleacetic acid) in
the cerebrospinal fluid [15].
The efficacy of SAM-e as an antidepressant has been
reported in a number of open-label trials [16] and in two
small placebo-controlled clinical trials [17,18]. Kagan et
al conducted a placebo-controlled trial that found SAM-e
to be effective in the treatment of depressed inpatients
[17]. A meta-analysis of SAM-e studies shows a greater
response rate with SAM-e compared with placebo, with a
global effect size ranging from 17–51% [19]. Side effects
reported in these studies are fewer than with SSRIs specif-
ically with respect to nausea, headache, dry mouth, and
agitation or activation. In studies of parenteral SAM-e,
activation of mania was noted in two cases [20]. SAM-e
would seem to offer the potential for effective antidepres-
sant treatment with fewer side effects for patients with
medical illnesses. This was shown in a successful open
label trial of SAM-e in Parkinson's patients [21] and in a
double-blind study of fibromyalgia patients [22]. The aim
of the study reported below was to assess efficacy, tolera-
bility, and safety of SAM-e in a group of HIV-positive indi-
viduals diagnosed with Major Depressive Disorder (DSM-
VI).
Methods
This study is an analysis of the complete dataset from an
independently funded, IRB-approved project conducted
at ACRIA, a 12-year-old, community-based HIV research
and education agency in New York City. A preliminary
report, based on a subset of these data, was presented at
the 14th International Conference on AIDS. A total of 20
patients were recruited between April 2000 and Novem-
ber 2000.
Recruitment activities included distribution of informa-
tion brochures to community physicians, announcements
at public ACRIA treatment education workshops, and
direct calls to persons listed in the ACRIA database. Indi-
viduals who responded to recruitment materials were
screened via phone by the research coordinator using the
PRIME-MD [23]. HIV-positive patients were then invited
to be interviewed by a study psychiatrist at ACRIA for a
clinical psychiatric examination. Patients who met DSM-
IV criteria for Major Depression (assessed with the SCID-
IV) and who did not meet any of the exclusion criteria
were eligible for participation after giving informed con-
sent [24]. Criteria for exclusion were (a) unstable medical
illness, (b) pregnancy, lactation or refusal by participants
to employ an acceptable contraceptive, (c) history of sub-
stance abuse in the prior month, (d) treatment with
another psychotropic medication within two weeks prior
to initiation of SAM-e treatment, (e) concurrent MAOI
treatment, (f) active suicidal ideation and/or psychotic
symptoms, (g) reversible medical pathology that is
thought to be causing the depression, and (h) history of
mania or diagnosed bipolar disorder. Patients received
$15 for each completed study visit.
Treatment was initiated at 200 mg of SAM-e twice a day
with daily supplementation of 1,000 mcg Vitamin B12
and 800 mcg Folic Acid, which were provided by Phar-
mavite, LLC. Over the course of the study, the dose of
SAM-e was individually adjusted up to 800 mg, twice
daily. Patients reporting nausea or insomnia were not
increased above 800 mg daily, while patients with no
reported side effects could be increased to a total daily
dose of 1600 mg. Dosing was adjusted according to the
severity of symptoms and clinical treatment response. We
defined clinical treatment response as an improvement in
depressive symptomatology of greater than 50% reduc-
tion on patient scores on the BDI and HAM-D as our treat-
ment endpoint [25,26]. A statistical data codebook was
created and secondary statistical analyses were performed.BMC Psychiatry 2004, 4:38 http://www.biomedcentral.com/1471-244X/4/38
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Measures
At each study visit (Baseline, Week 1, Week 2, Week 4,
Week 6, and Week 8), patients completed a clinical inter-
view and a series of structured questionnaires on medical/
physical symptoms, substance abuse, dementia scales, as
well as two instruments designed to measure depressive
symptoms, self-administered Beck Depression Inventory
(BDI and the clinician-administered HAM-D).
BDI
The BDI is a self-report measure for depressive symptoms
[25]. Total scores range from 0 – 63 and are calculated by
summing the scores to each of the 21 items. Higher scores
on this measure indicate greater severity of depression.
Scores above 30 indicate severe depression. Scores of 30 –
10 describe moderate depression, while scores less than
10 indicate the absence of depression.
HAM-D
The HAM-D is a 17-item, clinician-rated instrument. It
was designed to assess the changes in severity of depres-
sive symptomatology over time in patients who had been
diagnosed with Major Depressive Disorder [26]. Scores
above 24 reflect severe depression, while scores ranging
from 17 – 7 indicate mild symptomatology. Scores below
7 indicate an absence of depression.
Analyses
Two separate analyses (e.g., Baseline -v- Week 1 and Base-
line -v- Week 8) were identified as the most critical indica-
tors of SAM-e efficacy. The first analysis represented
evidence for acute onset of SAM-e, and the second indi-
cated effectiveness of SAM-e over time. BDI and HAM-D
scores were centered and the resulting Z-scores were used
in a series of t-tests to assess the agreement between
patient and investigator ratings of depression. Mean
scores from both depression measures (BDI and HAM-D)
were compared between time points, using a series of
paired t-tests. Finally, an intent-to-treat analysis, using the
last score carried forward, was conducted on patient BDI
scores for all subjects who initiated treatment.
Results
Participants
Thirty (30) subjects were screened by telephone and
twenty (20) entered into the study. Of these, fifteen (15)
were male, five (5) were female and the majority were
people of color (50% Black, 30% Hispanic, 20% Cauca-
sian). Table 1 presents a detailed demographic profile of
the patients. Although the exclusion criteria included a
prohibition against concurrent treatment with conven-
tional antidepressants during the study period, we identi-
fied one patient who did not discontinue use of
conventional antidepressant until Week 4 of the study. All
subjects self-reported that they were not actively substance
abusing at the time of the study; however, urine drug
screens were not performed. Five (5) patients did not
complete the study, but Week 1 data were recorded and
were included in the analysis of early onset of therapeutic
SAM-e effects. These five (5) subjects were excluded from
subsequent analyses. Two (2) subjects did not return for
study participation after Week 1: both had a history of
IDU; one was co-infected with Hepatitis C and had a
comorbid obsessive compulsive disorder (OCD). Three
(3) patients did not return after Week 4, one with a history
of IDU and one with a history of suicide attempts. Of
those who dropped out of the study, two (2) met criteria
for AIDS.
Treatment response
Table 2 contains the means, standard deviations and
ranges for depression data from each study visit. Of the
patients who provided Baseline and Week 1 follow-up
data, there was clear evidence for a rapid therapeutic effect
of SAM-e. The reduction in mean BDI scores from Base-
line (M = 33.5, SD = 11.1; Range: 15 – 55) to Week 1 (M
= 18.9, SD = 10.4; Range: 0 – 45) was significant, t(1, 18)
= 5.15, p < .001. Mean HAM-D scores declined in a paral-
lel manner, from Baseline (M = 26.5, SD = 6.8; Range: 12
– 39) to Week 1 (M = 16.8, SD = 7.3; Range: 2 – 29). This
change was also statistically significant, t(1, 14) = 3.58, p
< .01. Both depression assessment instruments reached
the defined clinical treatment response threshold of a
greater than 50 percent reduction in depression symptom
scores.
The 15 patients who completed the study also demon-
strated clinical treatment response over time. Mean BDI
scores dropped significantly from Baseline (M = 35.1, SD
Table 1: Demographic characteristics of patients
Variable N % Median Range
Age 20 45 24 – 57
Sex
Male 15 75.0
Female 5 25.0
Race/Ethnicity
Black 10 50.0
Hispanic 6 30.0
Caucasian 4 20.0
HIV diagnosis (year) 20 1992 1987 – 2000
CD-4 count (baseline) 20 320 5 – 1200
Log viral load (baseline) 20 3.40 1.70 – 4.48
Transmission risk
MSM sex 4 20.0
Heterosexual sex 5 25.0
IDU 2 10.0
Multiple risks 9 45.0BMC Psychiatry 2004, 4:38 http://www.biomedcentral.com/1471-244X/4/38
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= 12.0; Range: 15 – 55) to Week 8 (M = 5.1, SD = 4.8;
Range: 0 – 16), t(1, 14) = 8.28, p < .001. Similarly, HAM-
D scores were reduced from Baseline (M = 26.7, SD = 6.3;
Range: 12 – 36) to Week 8 (M = 3.7, SD = 3.3; Range: 1 –
13). The reduction in HAM-D scores reached statistical
significance, t(1, 13) = 9.92, p < .001.
There were no significant differences in patient and physi-
cian ratings of depression at each study visit (Table 3). Fig-
ures 1 and 2 provide graphic representations of mean BDI
and HAM-D scores across each time point, respectively.
Remission of depression was defined as a HAM-D score 
7, response to treatment was defined as  50% decrease
in HAM-D scores. For the 15 patients who completed the
study, the remission rate was 93%. Fourteen (14) of the
15 patients achieved a HAM-D of 7 or lower, while one
patient received a HAM-D rating of 13. The response rate
was also 93%, with 14 of the 15 patients achieving 50%
or greater reduction in HAM-D scores. The patient who
did not meet the response rate had a Baseline HAM-D of
12 and a Week 8 score of 7.
The intent-to-treat analysis yielded similar results. The last
reported BDI and HAM-D scores for each of the 20
patients who initiated treatment (i.e., received at least one
dose of SAM-e) were used in this analysis. Baseline BDI
scores (M = 33.5, SD = 11.1; Range: 15 – 55) were higher
than Week 8 (M = 6.6, SD = 6.1; Range: 0 – 21). HAM-D
scores dropped from Baseline (M = 26.5, SD = 6.8; Range:
12 – 39) to Week 8 (M = 7.7, SD = 10.1; Range: 1 – 39).
The reduction in self-reported (i.e., BDI) depressive symp-
tomatology was significant, t(1, 19) = 8.85, p < .001. The
results were equivalent for the psychiatrist-rated HAM-D,
t(1, 18) = 7.23, p < .001.
The intent-to-treat remission rate was 79%. Fifteen (15) of
the 20 patients achieved a HAM-D of 7 or lower, while
one patient did not receive a valid HAM-D rating and four
(4) received HAM-D ratings greater than 7 (13, 22, 24, 39,
respectively). The intent-to-treat response rate was 74%,
with 14 of the 19 patients achieving 50% or greater reduc-
tion in HAM-D scores.
Adverse effects
No patients terminated their participation due to side
effects. Two (2) patients reported nausea and one (1)
reported diarrhea; all resolved spontaneously. One (1)
patient had insomnia and a subjective feeling of 'high
energy,' but did not meet criteria for hypomania.
Discussion
Recent data from the HIV Cost and Services Utilization
Study (HCSUS) indicate that almost half the nation's
adult HIV patients suffered from symptoms of mental dis-
orders. The report indicates that the prevalence of mental
disorders range from four to eight times higher than those
Table 2: BDI and HAM-D scores recorded at each study visit
BDI HAM-D
Study Visit NM ( S D ) Range NM ( S D ) Range
Baseline 20 33.5(11.1) 15–55 20 26.5(6.8) 12–39
Week 1 19 18.9(10.4) 0–45 15 16.8(7.3) 2–29
Week 2 17 14.1(8.2) 0–25 13 10.7(5.5) 0–21
Week 4 17 8.8(7.8) 0–28 15 6.0(4.7) 0–15
Week 6 16 6.4(6.8) 0–20 14 5.2(5.7) 0–20
Week 8 16 5.0(4.7) 0–16 15 3.7(3.3) 1–13
Table 3: Comparison of BDI and HAM-D scores (study completers)
Study Visit td f p
Baseline -0.07 14 .95
Week 1 -1.39 14 .19
Week 2 -0.98 14 .35
Week 4 -0.64 14 .54
Week 6 0.35 13 .74
Week 8 0.71 14 .49BMC Psychiatry 2004, 4:38 http://www.biomedcentral.com/1471-244X/4/38
Page 5 of 6
(page number not for citation purposes)
found in the general populations. Over 60 percent of HIV-
positive adults used mental health or substance abuse
services during the period studied; 26% visited mental
health specialists, 15% had group mental health treat-
ment, 40% discussed emotional problems with medical
practitioners and 30% used psychotherapeutic medica-
tions [27].
Depression remains under-reported and under-treated in
the HIV population. Patient factors include stigma, fear of
more medication, and perhaps the assumption that
depression is a normal part of HIV disease, or due to
HAART. Physicians tend to focus more on physical symp-
toms, and may be unaware of how to screen for depres-
sion in this population. Both physicians and patients are
disadvantaged in accessing gay-affirmative, well-trained
HIV mental health specialists who can disentangle HIV
medical problems from substance abuse and mental ill-
ness. Risk factors for depression (e.g., history of substance
use/abuse, lack of social support, stigma, etc.) are preva-
lent in those populations who are disproportionately
affected by HIV. Many patients are reluctant to add more
medication to their complex treatment regimens. The
need for effective and safe treatments for depression is
clear.
Results of this study demonstrate that SAM-e significantly
reduces depression in people living with HIV. This finding
supports previous research demonstrating the efficacy of
SAM-e for use in treating depression. More importantly,
the therapeutic effect of SAM-e had an acute onset. There
were significant reductions in the severity of depression
among study patients within the first week of treatment.
Unlike most antidepressants that require several weeks to
reach maximum therapeutic efficacy, previous research
has shown that serum levels of SAM-e peak within 24
hours of treatment. This may account for the rapid, effects
of SAM-e seen on the HAM-D and BDI scores.
Conclusions
SAM-e is a safe, effective treatment for depression among
people living with HIV. SAMe has few reported side
effects, and in our population of PLWH, was extremely
well tolerated. SAM-e in this group had rapid onset of clin-
ical efficacy. Both of these results make it an appealing
alternative therapy for the management of depression in
the HIV population.
The results of the current study must be interpreted in the
context of the study's limitations. Limitations of this study
include the lack of a placebo group, the lack of a double-
blind design and small sample size. The criteria for partic-
ipation and the small sample size may limit the generaliz-
ability of our findings to other patient populations.
Without a placebo control group, we cannot assess two
factors that might have affected our results. Although
patients were treatment-experienced with other anti-
depressants, we cannot rule out the potential placebo-
response that may have contributed to the rapid therapeu-
tic effect of SAM-e. Also, meeting with a study psychiatrist
may have contributed to improved depressive symptom
ratings. Nonetheless, the study results provide useful and
clinically relevant information for treating depression in
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HIV-positive individuals. Future studies employing a dou-
ble-blind, placebo-control design are warranted.
The absence of depression does not imply wellness. Many
people living with HIV/AIDS report feelings of sadness
and depression but do not receive treatment for depres-
sion. Future studies should also assess health-related qual-
ity of life. Such protocols would determine if people with
significant, but subclinical depressive symptomatology
would benefit from SAM-e.
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